Clinical Trials Directory

Trials / Completed

CompletedNCT02017275

Comparison of BuMA eG Based BioDegradable Polymer Stent With EXCEL Biodegradable Polymer Sirolimus-eluting Stent in "Real-World" Practice

A Prospective, Multicenter, RAndomized, CoNtrolled, Study Comparing the Safety and Efficacy Between BuMA eG Based BioDegradable Polymer Stent and EXCEL Biodegradable Polymer Sirolimus-eluting Stent in "ReAl-World" Practice (PANDA-III)

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
2,348 (actual)
Sponsor
Sino Medical Sciences Technology Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

PANDA III is sought to investigate the safety and efficacy of a PLGA-polymer with electro-grafting base layer sirolimus-eluting stent (SES) versus a PLA-polymer SES at 12 months follow-up.

Detailed description

The BuMA stent (SINOMED, Beijing, China) was a novel biodegradable PLGA polymer sirolimus-eluting stent (SES), with design of adding an electro-grafting (eG) base layer between the polymer and the stainless steel stent strut.The eG layer can secure adhesion of the biodegradable PLGA coating as a result of the interdigitation, and the PLGA coating ensures 100% drug release within 30 days.The initial investigation showed a high strut coverage rate in both the BuMA stent and the Xience V stent at 3 months follow-up. Moreover, earlier vascular healing after drug-eluting stent implantation may reduce the incidence of stent thrombosis at follow-up and potentially shorten dual antiplatelet therapy duration. Therefore, we performed this randomized trial to investigate 12 months target lesion failure between the BuMA and the EXCEL stent, both with same eluted drug sirolimus, however different biodegradable polymer carriers.

Conditions

Interventions

TypeNameDescription
DEVICEBuMAThis group will contain 1175 subjects.
DEVICEEXCELThis group will contain 1175 subjects.

Timeline

Start date
2013-11-01
Primary completion
2015-09-01
First posted
2013-12-20
Last updated
2016-03-14

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02017275. Inclusion in this directory is not an endorsement.